In comparison to the discovery cohort, the identified EV proteins (i.e., SERPINA3, LRG1, and SCGB3A1) gained from the validation cohort clearly complied with the discovery cohort, which indicated the effect of the identified EV proteins on prostate cancer were stable (Figure 5c). Here, LRG1 is linked to prostate cancer.